tirzepatide slow responder for Weight Loss & Diabetes Weight Loss Timeline on Tirzepatide:

The counterargument is that subcutaneous delivery is more bioavailable than oral delivery, but even accounting for that difference, the dose is modest by any standard

New York, NY, USA: 2013

Users need to monitor for signs of depression and unusual conduct, and suicidal thoughts.Conflicted evidenceThe JAMA research evaluated four semaglutide clinical trials, which demonstrated psychiatric adverse events occurred at rates comparable to placebo in participants, without pre-existing conditions

Genetic Predisposition and Peptide Pathway Sensitivity Recent genetic research has identified variants in GLP1R (rs6923761), GIPR (rs1800437), and metabolic genes (FTO rs9939609, MC4R rs17782313) that correlate with GLP-1 and GIP receptor expression and function